Related references
Note: Only part of the references are listed.Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
Sanaz Ghafouri et al.
BONE MARROW TRANSPLANTATION (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S. Neelapu et al.
BLOOD (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Sham Mailankody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
Wendy Osborne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Caron A. Jacobson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas
Shengnan Ding et al.
TARGETED ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies
Malgorzata Bobrowicz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas
Rui Zhang et al.
BLOOD (2020)
Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
Nathan H. Fowler et al.
BLOOD (2020)
CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study
Yongxian Hu et al.
BLOOD (2020)
Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Gloria Iacoboni et al.
BLOOD (2020)
Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Maria Lia Palomba et al.
BLOOD (2020)
Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Peter Borchmann et al.
BLOOD (2020)
A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies
Jae H. Park et al.
BLOOD (2020)
CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells
Inkook Chun et al.
BLOOD (2020)
Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy
Olivia C. Finney et al.
BLOOD (2020)
Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
Ankit Kansagra et al.
BLOOD (2020)
Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study
Yi Lin et al.
BLOOD (2020)
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes
Melissa Alsina et al.
BLOOD (2020)
Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies
Caitlin L. Costello et al.
BLOOD (2020)
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Deepu Madduri et al.
BLOOD (2020)
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
Sham Mailankody et al.
BLOOD (2020)
Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
Sattva S. Neelapu et al.
BLOOD (2020)
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Maria Ormhoj et al.
CLINICAL CANCER RESEARCH (2019)
Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study
Alison R. Sehgal et al.
BLOOD (2019)
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Bhagirathbhai R. Dholaria et al.
BIODRUGS (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
Alfredo Rivas-Delgado et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Najat Bouchkouj et al.
CLINICAL CANCER RESEARCH (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts et al.
BLOOD ADVANCES (2019)
Pharmacologic control of CAR-T cell function using dasatinib
Evan W. Weber et al.
BLOOD ADVANCES (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo Gonzalez et al.
GENES & DEVELOPMENT (2018)
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)
Sham Mailankody et al.
BLOOD (2018)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M. Maciocia et al.
NATURE MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
Michael Hudecek et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Postibrutinib outcomes in patients with mantle cell lymphoma
Peter Martin et al.
BLOOD (2016)
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting B-cell maturation antigen in multiple myeloma
Yu-Tzu Tai et al.
IMMUNOTHERAPY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
piggyBac-ing models and new therapeutic strategries
Lauren E. Woodard et al.
TRENDS IN BIOTECHNOLOGY (2015)
Overcoming nutrient limitations for cell-based production of influenza vaccine
Sara Yousef et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
Jonathan L. Kaufman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma
P. Bertrand et al.
GENES CHROMOSOMES & CANCER (2013)
Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule
Antonella Chillemi et al.
MOLECULAR MEDICINE (2013)
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Maria Themeli et al.
NATURE BIOTECHNOLOGY (2013)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
ROR1 expression is not a unique marker of CLL
Gabor Barna et al.
HEMATOLOGICAL ONCOLOGY (2011)
ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia
H. Elizabeth Broome et al.
LEUKEMIA RESEARCH (2011)
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen
S. Peinert et al.
GENE THERAPY (2010)
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0
Ritsuro Suzuki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
Stacey R. Dillon et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Fabio Malavasi et al.
PHYSIOLOGICAL REVIEWS (2008)
Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL
Katsuya Nagatani et al.
ARTHRITIS AND RHEUMATISM (2007)
Cancer/testis genes in multiple myeloma:: Expression patterns and prognosis value determined by microarray analysis
Maud Condomines et al.
JOURNAL OF IMMUNOLOGY (2007)
Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score
Philip Went et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
YT Tai et al.
CANCER RESEARCH (2005)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
CD74 is expressed by multiple myeloma and is a promising target for therapy
JD Burton et al.
CLINICAL CANCER RESEARCH (2004)
Non-B, non-T neoplasms with lymphoblast morphology - Further clarification and classification
K Karube et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Share Paper
